An Artful Deal? Critics Question Administration’s Prescription Drug Negotiation Tools for Medicare Advantage
Co-Author: Nina Zhang, Stephenson Acquisto & Colman This article addresses the high-level challenges of tackling drug pricing policy related to prices that seniors and government programs pay, as well as the potential effects that the Trump administration’s policy efforts could have on those prices.1 Starting in January 2019, the Centers for Medicare & Medicaid Services…… Continue reading this entry